Stock BIOPOR BIOPORTO A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioPorto A/S

Equities

BIOPOR

DK0011048619

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:45:53 2024-04-26 am EDT 		5-day change 1st Jan Change
1.24 DKK +0.49% Intraday chart for BioPorto A/S -1.43% -40.67%
Apr. 10 BioPorto Names New Chief Legal Officer MT
Apr. 10 Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization 1 512.5 1,077 661.3 774.8 793.5 470.8
Enterprise Value (EV) 1 496 1,077 661.3 774.8 793.5 470.8
P/E ratio -7.15 x -13.5 x -11.8 x -9.65 x -13.1 x -12.4 x
Yield - - - - - -
Capitalization / Revenue 19.3 x 46.4 x 27.3 x 26.7 x 25.6 x 11.8 x
EV / Revenue 19.3 x 46.4 x 27.3 x 26.7 x 25.6 x 11.8 x
EV / EBITDA -7,500,752 x - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 174,931 266,569 267,741 334,680 379,657 379,657
Reference price 2 2.930 4.040 2.470 2.315 2.090 1.240
Announcement Date 2/26/20 3/17/21 4/6/22 3/30/23 4/4/24 -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales 1 26.62 23.2 24.25 28.97 30.96 40
EBITDA -68.33 - - - - -
EBIT 1 -74.3 -63.59 -65.26 -78.94 -60.16 -41
Operating Margin -279.09% -274.05% -269.05% -272.51% -194.34% -102.5%
Earnings before Tax (EBT) 1 -74.25 -66.83 -63.84 -81.55 -61.21 -41
Net income 1 -69.64 -61.56 -57.11 -75.92 -56.33 -38.13
Net margin -261.6% -265.31% -235.48% -262.08% -181.95% -95.32%
EPS 2 -0.4100 -0.3000 -0.2100 -0.2400 -0.1600 -0.1000
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 2/26/20 3/17/21 4/6/22 3/30/23 4/4/24 -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5.294 6.807 6.502 8.506 5.3 8.69 8.041 7.748 8.6 6.56 8.2 8.4 10.3 13.3
EBITDA - - - - - - - - - - - - - -
EBIT -14.48 -18.09 -18.22 -20.14 - -20.62 -16.95 -20.86 - -11.98 - - - -
Operating Margin -273.44% -265.7% -280.19% -236.74% - -237.28% -210.79% -269.17% - -182.65% - - - -
Earnings before Tax (EBT) -13.86 -17.74 -18.28 -19.38 - -25.1 -17.2 -20.97 - -12.42 - - - -
Net income -11.38 -16.74 -17.03 -17.09 - -24.92 -16.06 -19.65 - -11.02 - - - -
Net margin -215.04% -245.95% -261.92% -200.93% - -286.82% -199.73% -253.6% - -168% - - - -
EPS 2 -0.0400 -0.0600 -0.0600 -0.0500 - -0.0800 -0.0500 -0.0600 - -0.0300 -0.0300 -0.0300 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/17/21 4/6/22 5/11/22 8/17/22 11/9/22 3/30/23 5/10/23 8/1/23 10/31/23 4/4/24 - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position 16.6 - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 2.06 1.32 - - - -
Capex / Sales 7.75% 5.67% - - - -
Announcement Date 2/26/20 3/17/21 4/6/22 3/30/23 4/4/24 -
1DKK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.24 DKK
Average target price
5 DKK
Spread / Average Target
+303.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOPORTO A/S Stock BioPorto A/S
-40.67% 67.41M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. BIOPOR Stock
  4. Financials BioPorto A/S